Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FWBINASDAQ:KPRXNASDAQ:ONCRNASDAQ:PBLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFWBIFirst Wave BioPharma$3.28$2.33▼$60.00$7.34M1.28212,944 shs56,500 shsKPRXKiora Pharmaceuticals$3.13-2.2%$3.12$2.51▼$4.86$9.74M-0.68134,298 shs40,342 shsONCROncorus$0.13$0.07$0.01▼$0.47$3.29M3.61.33 million shs135,947 shsPBLAPanbela Therapeutics$0.25+6.7%$0.27$0.20▼$0.47$1.22M1.3518,430 shs286 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFWBIFirst Wave BioPharma0.00%0.00%0.00%0.00%0.00%KPRXKiora Pharmaceuticals0.00%+5.96%+4.58%-0.93%-13.98%ONCROncorus0.00%0.00%0.00%0.00%0.00%PBLAPanbela Therapeutics0.00%-21.77%-1.01%-27.34%-38.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFWBIFirst Wave BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AKPRXKiora Pharmaceuticals3.0934 of 5 stars3.55.00.00.01.91.70.6ONCROncorusN/AN/AN/AN/AN/AN/AN/AN/APBLAPanbela Therapeutics0.0475 of 5 stars0.03.00.00.00.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFWBIFirst Wave BioPharma 0.00N/AN/AN/AKPRXKiora Pharmaceuticals 3.00Buy$10.00219.49% UpsideONCROncorus 0.00N/AN/AN/APBLAPanbela Therapeutics 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest KPRX, PBLA, ONCR, and FWBI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025KPRXKiora PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFWBIFirst Wave BioPharmaN/AN/AN/AN/A$6.54 per shareN/AKPRXKiora Pharmaceuticals$16.02M0.59$1.21 per share2.58$8.58 per share0.36ONCROncorusN/AN/AN/AN/A$2.33 per shareN/APBLAPanbela TherapeuticsN/AN/AN/AN/A($18.37) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFWBIFirst Wave BioPharma-$15.80MN/A0.00N/AN/AN/A-102.83%-22.74%N/AKPRXKiora Pharmaceuticals$3.60M-$2.90N/AN/AN/AN/A-42.82%-32.18%8/8/2025 (Estimated)ONCROncorus-$77.42M-$3.49N/A∞N/AN/AN/AN/AN/APBLAPanbela Therapeutics-$25.26M-$71.13N/A∞N/AN/AN/A-302.61%8/11/2025 (Estimated)Latest KPRX, PBLA, ONCR, and FWBI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025KPRXKiora Pharmaceuticals-$0.77-$0.52+$0.25-$0.52$0.75 millionN/A3/25/2025Q4 2024KPRXKiora Pharmaceuticals-$0.64-$1.04-$0.40-$1.04$0.75 million$0.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFWBIFirst Wave BioPharmaN/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/AONCROncorusN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFWBIFirst Wave BioPharma0.401.211.58KPRXKiora PharmaceuticalsN/A5.145.14ONCROncorusN/AN/AN/APBLAPanbela TherapeuticsN/A0.260.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFWBIFirst Wave BioPharma12.30%KPRXKiora Pharmaceuticals76.97%ONCROncorus20.07%PBLAPanbela Therapeutics4.37%Insider OwnershipCompanyInsider OwnershipFWBIFirst Wave BioPharma0.49%KPRXKiora Pharmaceuticals0.05%ONCROncorus17.10%PBLAPanbela Therapeutics0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFWBIFirst Wave BioPharma92.48 million2.46 millionNot OptionableKPRXKiora Pharmaceuticals103.04 million3.04 millionNot OptionableONCROncorus6426.09 million21.63 millionOptionablePBLAPanbela Therapeutics64.86 million4.86 millionNot OptionableKPRX, PBLA, ONCR, and FWBI HeadlinesRecent News About These CompaniesHead-To-Head Analysis: Genmab A/S (OTCMKTS:GNMSF) and Panbela Therapeutics (NASDAQ:PBLA)June 15, 2025 | americanbankingnews.comPanbela Therapeutics Announces Q3 2024 Financial ResultsNovember 16, 2024 | markets.businessinsider.comPanbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q3 2024 Financial ResultsNovember 15, 2024 | finanznachrichten.dePanbela Therapeutics Inc (PBLA) Q3 2024 Earnings Call Highlights: Strategic Loan and Clinical ...November 15, 2024 | finance.yahoo.comPanbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comPanbela Provides Business Update and Reports Q3 2024 Financial ResultsNovember 14, 2024 | globenewswire.comPanbela Therapeutics (OTC:PBLA) Stock, Insider Trading ActivityOctober 6, 2024 | benzinga.comHorace Mann Educators (NYSE:HMN) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comPanbela Therapeutics (OTC:PBLA) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comPanbela Therapeutics, Inc. (NASDAQ:PBLA) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | insidermonkey.comPanbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | seekingalpha.comPanbela Provides Business Update and Reports Q2 2024 Financial ResultsAugust 13, 2024 | globenewswire.comIs Panbela Therapeutics Inc (PBLA) Stock a Good Investment?August 3, 2024 | aaii.comPanbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024July 30, 2024 | globenewswire.comPanbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial ModificationJune 24, 2024 | globenewswire.comPanbela Therapeutics Inc. (PBLA) Insider ActivityMay 25, 2024 | nasdaq.comHC Wainwright & Co. Downgrades Panbela Therapeutics (PBLA)May 17, 2024 | msn.comQ1 2024 Panbela Therapeutics Inc Earnings CallMay 16, 2024 | uk.finance.yahoo.comPanbela Therapeutics, Inc. (NASDAQ:PBLA) Q1 2024 Earnings Call TranscriptMay 16, 2024 | msn.comPanbela Therapeutics Inc (PBLA) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...May 16, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKPRX, PBLA, ONCR, and FWBI Company DescriptionsFirst Wave BioPharma NASDAQ:FWBIFirst Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.Kiora Pharmaceuticals NASDAQ:KPRX$3.13 -0.07 (-2.19%) Closing price 04:00 PM EasternExtended Trading$3.10 -0.03 (-0.96%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.Oncorus NASDAQ:ONCROncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.Panbela Therapeutics NASDAQ:PBLA$0.25 +0.02 (+6.73%) As of 01:36 PM EasternPanbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
